News
We send the latest information from SMC Laboratories.
Continuum Biosciences’s publication in Journal of Medicinal Chemistry
SMC announces that Continuum Biosciences, Pty Ltd. has published the results of a study using STAM model on Journal of Medicinal Chemistry (https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00542) . Title: “6-Amino-[1,2,5]oxadiazolo[3,4-b]pyrazin-5-ol Derivatives as Efficacious Mitochondrial Uncouplers in STAM Mouse Model of Non-alcoholic Steatohepatitis”
Sabinsa Corporation’s publication in Scientific Reports
SMC announces that Sabinsa Corporation has published the results of a study using STAM model in Scientific Reports. Title: “Novel Combinatorial Regimen of Garcinol and Curcuminoids for Non-alcoholic Steatohepatitis (NASH) in Mice”
Juntendo University’s publication on European Radiology Experimental
SMC announces that Juntendo University has published the results of a study using STAM™ model in European Radiology Experimental. Title: “Free fatty acid-based low-impedance liver image: a characteristic appearnace in nonalcoholic steatohepatitis (NASH)” Free fatty acid-based low-impedance liver image: a characteristic appearance in nonalcoholic steatohepatitis (NASH) | European Radiology Experimental | Full Text (springeropen.com)…
Genomics Institute of the Novartis Research Foundation’s publication on Journal of Medicinal Chemistry
SMC announces that Genomics Institute of the Novartis Research Foundation has published the results of a study using STAM™ model in Journal of Medicinal Chemistry. Title: “Nidufexor (LMB763), a Novel FXR Modulator for the Treatment of Nonalcoholic Steatohepatitis” Nidufexor (LMB763), a Novel FXR Modulator for the Treatment of Nonalcoholic Steatohepatitis | Journal of Medicinal…
Can-Fite BioPharma’s publication on International Journal of Molecular Medicine
SMC announces that Can-Fite BioPharma has published the results of a study using STAM™ model in International Journal of Molecular Medicine. Title: “The A3 adenosine receptor agonist, namodenoson, ameliorates non-alcoholic steatohepatitis in mice” The A3 adenosine receptor agonist, namodenoson, ameliorates non‑alcoholic steatohepatitis in mice (spandidos-publications.com)
Pfizer’s publication on Science Translational Medicine.
SMC announces that Pfizer has published the results of a study using STAM™ model in Science Translational Medicine. Title: “Targeting diacylglycerol acyltransferase 2 for the treatment of nonalcoholic steatohepatitis” Targeting diacylglycerol acyltransferase 2 for the treatment of nonalcoholic steatohepatitis | Science Translational Medicine (sciencemag.org)
ChemomAb’s publication on JHEP Reports.
SMC announces that ChemomAb has published the results of a study using STAM™ model in JHEP Reports. Title: “A Blocking Monoclonal Antibody to CCL24 Alleviates Liver Fibrosis and Inflammation in Experimental Models for Liver Damage” A blocking monoclonal antibody to CCL24 alleviates liver fibrosis and inflammation in experimental models of liver damage – ScienceDirect…
Enzychem Lifesciences Corporation’s presentation at AASLD The Liver Meeting® 2019 in Boston.
SMC announced that Enzychem Lifesciences Corporation presented results of a study using STAM™ model at poster presentation at AASLD The Liver Meeting® 2019 in Boston, MA, November 8-12, 2019. Title: “EC-18, a novel immune resolution accelerator, improves NASH and liver fibrosis”
Enyo Pharma SA’s presentation at AASLD The Liver Meeting® 2019 in Boston.
SMC announced that Enyo Pharma SA presented results of a study using STAM™ model at poster presentation at AASLD The Liver Meeting® 2019 in Boston, MA, November 8-12, 2019. Title: “In vitro and in vivo characterization of EYP001 a novel, potent and selective FXR agonist now in a phase 2 clinical trial in NASH”
Dr. Falk Pharma GmbH’s presentation at AASLD The Liver Meeting® 2019 in Boston.
SMC announced that Dr. Falk Pharma GmbH presented results of a study using STAM™ model at poster presentation at AASLD The Liver Meeting® 2019 in Boston, MA, November 8-12, 2019. Title: “Norursodeoxycholic acid (norUDCA) significantly ameliorates liver injury in the STAM mouse model for non-alcoholic steatohepatitis (NASH)”